Background: DSA are associated with reduced long-term transplant function and increased prevalence of chronic rejection in some patients, whereas others do not: our goal was to determine whether the sialylation of IgG and DSA could help to explain in these last cases their "non-aggressive" and/or "protective" biological activity.
Methods: The sialylation level of total IgG in blood from two groups of kidney-transplant patients with de novo DSA, one with an AMR (DSAAMR), and the other without were studied.
Results: In the DSAAMR patients total IgG were more sialylated at time of transplant, and at the first detection of DSA, class I DSA were 2.6-fold more sialylated (mean 9.943±1.801 versus 3.898±2.475, p=0.058); DSAAMR patients exhibited higher levels of class II DSA.
Conclusions: In our study, higher levels of sialylated IgG are detectable on day of transplant in patients who do not develop AMR, they have higher sialylated class I DSA at the initial detection of DSA, whereas class II DSA are significantly higher in patients who develop AMR. This is the first report suggesting that transplant outcome, and particularly AMR, is associated with levels of sialylated IgG antibodies. Our data suggest that DSA are functionally heterogeneous and that further studies with an enlarged cohort may improve our understanding of their clinical impact.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.humimm.2015.10.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HLA and Non-HLA Factors for Donor Selection in Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide GvHD Prophylaxis.
Cells
December 2024
Cleveland Clinic, Allogen, Pathology & Laboratory Medicine Institute, Cleveland, OH 44195, USA.
Human leukocyte antigen (HLA) mismatches in stem cell transplantation can be well-tolerated with the use of post-transplant cyclophosphamide (PTCy) for graft-versus-host-disease (GvHD) prophylaxis. Haploidentical (Haplo) and HLA-mismatched unrelated donors become acceptable donors. This review focuses on Haplo and unrelated donor selection in the context of PTCy-transplant for hematological malignancy, in comparison with conventional GvHD prophylaxis.
View Article and Find Full Text PDFAssessing the Predictive Power of PIRCHE-II Scores for the Development of Donor-Specific Antibodies After Simultaneous Pancreas-Kidney Transplantation.
Transpl Int
January 2025
Department of Nephrology, University Hospital Zurich, Zurich, Switzerland.
Article Synopsis
- The study investigates the development of donor-specific antibodies (dnDSA) in simultaneous pancreas/kidney transplant recipients (SPKTRs) compared to kidney transplant recipients (KTRs), finding a higher incidence of dnDSA in SPKTRs at one year post-transplant.
- Independent risk factors for dnDSA development identified include preformed DSA and younger donor age, with high PIRCHE-II scores for HLA-DQ correlating significantly with dnDSA.
- However, the research highlights that total PIRCHE-II scores may not reliably predict dnDSA risk, suggesting caution in using this measure for post-transplant assessment.
Severe SARS-CoV-2 infection is associated with increased risk of De novo HLA antibody production in lung transplant recipients: Single-center study.
Transpl Immunol
December 2024
Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, United States of America. Electronic address:
Article Synopsis
- The COVID-19 pandemic has negatively affected lung transplant recipients (LTR), raising concerns about the risk of developing de-novo HLA donor-specific antibodies (DSA) after infection, particularly with changes in immunosuppressive treatment.
- A study reviewed 63 LTR diagnosed with COVID-19, categorizing disease severity into mild, moderate, and severe to analyze the impact on HLA DSA production.
- Results indicated no significant changes in antibody levels or de-novo DSA occurrence for most patients over a six-month period post-COVID-19 diagnosis, although a small percentage of those with severe COVID-19 did show new DSA development.
Clinical Applicability of 2-Field High-Resolution and Extended HLA-Allele Typing in Deceased Donor Kidney Allocation.
HLA
December 2024
Department of Renal Medicine and Transplantation, Sir Charles Gairdner Hospital, Perth, Australia.
HLA-compatibility remains an important triage test for deceased donor kidney allocation. Low-intermediate resolution donor HLA-typing is typically available at allocation, but its accuracy in assigning pre-transplant donor-specific anti-HLA antibody (DSA) and HLA mismatches compared to 2-field high-resolution typing is poorly characterised. Consecutive deceased donor/recipient pairs from a single centre between 2016 and 2020 were included.
View Article and Find Full Text PDFDSA-based perfusion parameters versus TICI score after mechanical thrombectomy in acute ischaemic stroke patients: a congruence analysis.
Eur Radiol Exp
December 2024
Department of Neuroradiology, University Medical Center, Johannes Gutenberg-University of Mainz, Mainz, Germany.
Background: Several factors are frequently considered for outcome prediction rin stroke patients. We assessed the value of digital subtraction angiography (DSA)-based brain perfusion measurements after mechanical thrombectomy (MT) for outcome prediction in acute ischaemic stroke.
Methods: From DSA image data (n = 90; 38 females; age 73.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!